People channel feed

All of the news, delivered with full-text to your inbox. For professionals discovering, developing, and marketing biopharmaceutical drugs.

SUBSCRIBE NOW
Subscribe to Endpoints News
Victor Bulto [via Dermatology Education Foundation on YouTube]

Make that 2 new US Big Phar­ma chiefs to­day, as No­var­tis re­makes top team

Today we get two new Big Pharma chiefs for the US market.

This morning GlaxoSmithKline led the way with the news that they recruited Merck KGaA’s Maya Martinez-Davis for the role of US pharma president. And Novartis, which has been remaking its own top ranks, followed by announcing that Fabrice Chouraqui is stepping down from that same role and will be replaced by Victor Bulto, who has championed Cosentyx in the US.

Endpoints News

Basic subscription required

Unlock this story instantly and join 57,900+ biopharma pros reading Endpoints daily — and it's free.

Maya Martinez-Davis via Linkedin

Shift­ing fo­cus to on­col­o­gy, GSK re­cruits a can­cer vet as new chief of US phar­ma­ceu­ti­cals — adding an­oth­er woman to the top ranks of bio­phar­ma

Jack Bailey GSK

The slow-moving overhaul of the leadership and strategy at GSK is taking a fresh turn today, and bringing another woman to the top ranks of the industry.

GlaxoSmithKline said today that US pharmaceuticals president Jack Bailey “has decided to step down” at the end of the year.

Endpoints News

Basic subscription required

Unlock this story instantly and join 57,900+ biopharma pros reading Endpoints daily — and it's free.

Andrew Trister via GitHub

Key Ap­ple dig­i­tal health re­searcher set to join the Gates Foun­da­tion — re­port

Last week, Apple revealed it was working with Eli Lilly on detecting dementia in its early stages — and now a co-author of the study is reportedly heading to the Bill and Melinda Gates Foundation.

The scientist, Andrew Trister, joined Apple in April 2016 in a ‘special projects’ role — before the tech giant’s big ambitions in health care were thrust into the spotlight.

In an interview with CNBC on Friday, Trister confirmed he was departing to take on the role of digital health innovation at the Gates Foundation — where he is set to work with entrepreneurs that are thinking of bringing digital health technologies from the United States to developing nations, where smartphones are increasingly becoming all-pervasive. In addition, he will also invest in projects located under-resourced regions, such as rural Africa and India, the report said.

Martin Shkreli. AP Images

Retrophin paid Mar­tin Shkre­li 'undis­closed sum' to set­tle years­long le­gal dis­putes

Remember when Retrophin disclosed in June that it’s finally settled up the four-year legal saga with founder and former CEO Martin Shkreli? In an update for investors on Wednesday, the company added that it had paid an undisclosed sum to the infamous biotech exec and financier as part of the agreement — though it won’t say how much.

Shkreli, who’s serving a 7-year prison sentence for defrauding investors of his hedge funds, had “agreed to extinguish his rights to future advancement of legal fees and indemnification by the company (other than for certain pending litigation), and to abide by certain standstill restrictions,” the company added in a 10-Q filing first reported by CNBC.

John Johnson, via W20

Melin­ta chief John John­son jumps ship — with the chair­man — from an­oth­er trou­bled an­tibi­otics play

Just 9 months after taking the reins at Melinta, the experienced biotech exec John Johnson is whirling back out through the revolving door to the C suite at the troubled antibiotics company.

Endpoints News

Basic subscription required

Unlock this story instantly and join 57,900+ biopharma pros reading Endpoints daily — and it's free.

John McHutchison, Getty Images

Gilead­'s new­ly de­part­ed R&D chief re-emerges as CEO of a ri­val hep B biotech look­ing to make a come­back

Just a few weeks after taking his $1.1 million severance check from Gilead, John McHutchison has re-emerged as the new CEO of Assembly Biosciences $ASMB, which has seen its share price swoon as investors lost confidence in its ability to compete with Gilead with its experimental hepatitis B drug.

Endpoints News

Basic subscription required

Unlock this story instantly and join 57,900+ biopharma pros reading Endpoints daily — and it's free.

Josh Bilenker, Loxo

Loxo chief Josh Bilenker steps in (tem­porar­i­ly) to head on­col­o­gy R&D at Eli Lil­ly as Levi Gar­raway steps out

Josh Bilenker didn’t just gain a personal windfall by selling Loxo to Eli Lilly for $8.1 billion. He got a new, if temporary, job out of the deal as well.

Endpoints News

Basic subscription required

Unlock this story instantly and join 57,900+ biopharma pros reading Endpoints daily — and it's free.

Michael McClellan, Teva

Te­va to lose CFO, with turn­around still un­der con­struc­tion

Two years ago, Kåre Schultz took on the gargantuan challenge of fixing a financially troubled, debt-laden Teva with a sparse pipeline. He responded by initiating a sweeping restructuring by cutting thousands of jobs, executing facility closures, trimming board compensation and overhauling the Isreal-based company’s senior executive team. One of his moves was to officially promote Michael McClellan to chief financial officer. Along with its second-quarter results on Wednesday, Teva said McClellan was departing for personal reasons.

Part pro­ce­dure, part drug: Robert Ang joins Sid­dhartha Mukher­jee in pi­o­neer­ing a new type of cell en­gi­neer­ing

In a recent chronicle on the promise and price of cell therapies, Siddhartha Mukherjee — author, oncologist and Columbia professor among his other titles — mused about how engineered T cells had blurred the traditional boundaries separating a procedure and a drug. “Procedures come alive in the tinkering, fussing hands of their operators,” he observed, while a “drug, in contrast, is a depersonalized entity.” For the new generation of meticulously manufactured CAR-T to reach the masses, innovators must marry the iterative nature of a procedure with the production efficiency of a drug — and add a ruthless pursuit of the leanest, cheapest process possible.

Rafael Amado

Join­ing Chang and Bellde­grun, Rafael Ama­do takes a lead­ing R&D post in the next big cell ther­a­py rev­o­lu­tion

Rafael Amado spent close to 5 years at Adaptimmune looking to break new ground in the TCR field of oncology, going inside cells to find new targets to combat cancer. As of today, he’s making a switch to the cutting edge of one of the hottest fields in cell therapies, where he’ll be expected to take a lead role on a front-running charge at an off-the-shelf approach in CAR-T.

The GlaxoSmithKline veteran — and former head of their oncology research group — officially left Adaptimmune last week. Now he’s coming up on the other side of the weekend as the new head of R&D at Allogene, run by Kite vets David Chang and Arie Belldegrun. He’ll start at the beginning of September.

This is the next generation of engineered CAR-Ts, designed to unleash a massive immune system attack on cancer that can be curative for many patients. There’s a rapid assault at gaining the pioneering OK underway. And Amado plans to be an important part of it.

Endpoints News

Basic subscription required

Unlock this story instantly and join 57,900+ biopharma pros reading Endpoints daily — and it's free.